Latest news with #NVST
Yahoo
28-05-2025
- Business
- Yahoo
Baird Upgrades Envista Holdings (NVST) Stock to Outperform, Raises PT
On May 27, Baird analyst Jeff Johnson upgraded the stance on Envista Holdings Corporation (NYSE:NVST)'s stock from 'Neutral' to 'Outperform,' and raised its price objective to $23.00 from the prior target of $21.00, as reported by The Fly. A close-up of a dental bracket and wires being fitted into a patient's mouth. The firm's May domestic dental survey showed an improvement following the disappointing April findings. The firm added that its feedback continues to hint at stable-to-slightly improved dental demand over the last couple of months, including in the US. The firm expects revenue and earnings upside for Envista Holdings Corporation (NYSE:NVST) in 2025 and 2026. Baird also added that stable end markets and the recent relief to China on tariffs are some of the factors likely to support the upside over the next couple of quarters. Envista Holdings Corporation (NYSE:NVST) highlighted that the global dental market remained stable in Q1 2025 as the underlying demand remained similar to what the company saw in H2 2024. Amidst geopolitical uncertainty, the company continues to ramp up its mitigating actions to further increase its resiliency. Notably, the restructuring and additional cost controls continue to result in G&A productivity across the company. Envista Holdings Corporation (NYSE:NVST) is engaged in developing, manufacturing, marketing, and selling dental products. While we acknowledge the potential of NVST to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVST and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Baird Upgrades Envista Holdings (NVST) Stock to Outperform, Raises PT
On May 27, Baird analyst Jeff Johnson upgraded the stance on Envista Holdings Corporation (NYSE:NVST)'s stock from 'Neutral' to 'Outperform,' and raised its price objective to $23.00 from the prior target of $21.00, as reported by The Fly. A close-up of a dental bracket and wires being fitted into a patient's mouth. The firm's May domestic dental survey showed an improvement following the disappointing April findings. The firm added that its feedback continues to hint at stable-to-slightly improved dental demand over the last couple of months, including in the US. The firm expects revenue and earnings upside for Envista Holdings Corporation (NYSE:NVST) in 2025 and 2026. Baird also added that stable end markets and the recent relief to China on tariffs are some of the factors likely to support the upside over the next couple of quarters. Envista Holdings Corporation (NYSE:NVST) highlighted that the global dental market remained stable in Q1 2025 as the underlying demand remained similar to what the company saw in H2 2024. Amidst geopolitical uncertainty, the company continues to ramp up its mitigating actions to further increase its resiliency. Notably, the restructuring and additional cost controls continue to result in G&A productivity across the company. Envista Holdings Corporation (NYSE:NVST) is engaged in developing, manufacturing, marketing, and selling dental products. While we acknowledge the potential of NVST to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVST and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Envista, Hitachi Digital Services announce 5-year strategic IT partnership
Hitachi Digital Services, the digital consultancy and technology services subsidiary of Hitachi, Ltd. (HTHIY), announced a five-year agreement with Envista Holdings Corporation (NVST) to deliver end-to-end IT managed services across Envista's operations in more than 60 countries. Under this agreement, Hitachi Digital Services will provide 24/7 global IT services-including application support, network infrastructure, analytics and business intelligence, and cybersecurity-through its global delivery centers in India, Mexico, Portugal, the U.S. and Vietnam. Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on NVST: Disclaimer & DisclosureReport an Issue Envista price target raised to $24 from $23 at BofA Envista price target lowered to $18 from $21 at UBS Cautious Outlook on Envista Holdings Amid Uncertain Dental Demand and Geographic Challenges Envista Holdings' Earnings Call: Balanced Growth Amid Challenges Envista price target lowered to $21 from $23 at Baird
Yahoo
16-05-2025
- Business
- Yahoo
NVST Q1 Earnings Call: Resilient Revenue Amid Tariff Uncertainty and Margin Pressures
Dental products company Envista Holdings (NYSE:NVST) reported revenue ahead of Wall Street's expectations in Q1 CY2025, but sales fell by 1.1% year on year to $616.9 million. Its non-GAAP profit of $0.24 per share was 17.1% above analysts' consensus estimates. Is now the time to buy NVST? Find out in our full research report (it's free). Revenue: $616.9 million vs analyst estimates of $608.3 million (1.1% year-on-year decline, 1.4% beat) Adjusted EPS: $0.24 vs analyst estimates of $0.20 (17.1% beat) Adjusted EBITDA: $79 million vs analyst estimates of $76.37 million (12.8% margin, 3.4% beat) Management reiterated its full-year Adjusted EPS guidance of $1 at the midpoint Operating Margin: 6.3%, down from 7.7% in the same quarter last year Free Cash Flow was -$5.6 million, down from $29.3 million in the same quarter last year Constant Currency Revenue was flat year on year, in line with the same quarter last year Market Capitalization: $3.07 billion Envista's first-quarter results were shaped by steady demand across most of its dental portfolio, with management highlighting operational progress in consumables, premium implants, and orthodontics outside China. CEO Paul Keel noted, 'We delivered core growth of 0.2% and adjusted EBITDA margin around 13%, both in line with our expectations,' while emphasizing that the company's broad-based business model helped offset regional and product-specific headwinds. Management attributed the slight year-over-year sales decline to unfavorable foreign exchange rates and two fewer billing days, with price increases and productivity gains partially mitigating these factors. Looking ahead, management reiterated its full-year profit guidance, but addressed wider risks tied to ongoing tariff changes and macroeconomic uncertainty. The company's leadership discussed efforts to offset tariff impacts by shifting supply chains and increasing pricing where possible. Keel acknowledged, 'We are maintaining our 2025 guidance… albeit with a wider confidence interval for the reasons just mentioned,' and stressed that dental remains a relatively stable industry but is not immune to consumer confidence trends or cost inflation. Envista's management focused on the impact of external pressures and the company's operational agility in navigating a complex global environment, while also highlighting strategic initiatives underway. Tariff Mitigation Efforts: Management described the creation of a dedicated tariff task force and detailed supply chain adjustments, including shifting manufacturing of premium implants from the U.S. to Sweden for the Chinese market and qualifying additional suppliers to diversify risk. These actions are intended to offset costs from new and potential tariffs between the U.S., China, and Europe. Segment Growth Drivers: Growth was reported in consumables, premium implants, and orthodontics outside China, with strong customer service levels and productivity improvements. Management cited stable performance in North America, Japan, and emerging markets, and noted that flat European results reflected broader market conditions. Operational Efficiency Initiatives: The company achieved record Spark unit cost reductions and improved general and administrative (G&A) productivity, supported by restructuring and ongoing cost control measures. These operational gains were credited with helping to offset foreign exchange and margin pressures. China VBP (Volume-Based Procurement) Developments: Management explained that the implementation of VBP in China's orthodontics market is proceeding as anticipated, with expectations for a soft first half followed by benefits in the second half if market share consolidates as happened in prior implant tenders. People and Leadership Updates: Envista reported a notable increase in employee engagement and retention, attributing some of the progress to recent leadership changes and a blend of industry experience with new perspectives from other sectors. These people-focused efforts are seen as foundational to maintaining execution during uncertain times. Management's outlook for the remainder of the year is centered on the successful mitigation of tariff impacts, steady demand for non-elective dental procedures, and ongoing cost reduction initiatives, balanced against macroeconomic headwinds. Tariff and Supply Chain Flexibility: Envista's ability to shift manufacturing locations and qualify new suppliers is expected to help offset the cost of current tariffs, but management noted that the environment remains fluid and risks of further changes persist. China VBP and Market Consolidation: The timing and outcome of Volume-Based Procurement in China will be pivotal, especially for orthodontics, as management anticipates a recovery in the second half if the company can capture additional volume as larger players did during previous VBP cycles. Operational Productivity and Pricing Strategy: Further gains in Spark margin, continued G&A productivity, and price realization are set to drive profitability. However, management cautioned that pricing power varies by geography and product, with greater sensitivity in U.S. markets and commodity categories. Jon Block (Stifel): Asked for specifics on tariff exposure and mitigation, to which CEO Paul Keel detailed supply chain shifts and supplier diversification, emphasizing ongoing adjustments as the environment evolves. Jason Bednar (Piper Sandler): Probed the net impact of tariffs and the confidence in mitigation, with management stating guidance incorporates current tariffs but confidence is "less certain" due to volatility, and that outcomes in the second half depend on successful execution of planned actions. Elizabeth Anderson (Evercore ISI): Queried expectations and guidance assumptions for China's Volume-Based Procurement, with Keel confirming the process is tracking expectations and projecting a benefit in the second half as market share consolidates. Jeff Johnson (Baird): Sought clarity on price realization as a tariff mitigation strategy, prompting Keel to outline that pricing power is strongest in differentiated products and weaker in commodity segments, especially in the U.S. Allen Lutz (Bank of America): Asked about the performance divergence between premium and Challenger implants, with management attributing Challenger's softness to fewer billing days and stating there is no expected change to its long-term growth trajectory. In the coming quarters, the StockStory team will monitor (1) Envista's execution of supply chain shifts and tariff mitigation strategies, (2) progress and volume gains from China's Volume-Based Procurement in orthodontics, and (3) further improvements in Spark margins and overall cost productivity. Additionally, we will track management's ability to sustain price realization in competitive and cost-sensitive markets, especially in light of macroeconomic pressures. Envista currently trades at a forward P/E ratio of 17.7×. Should you load up, cash out, or stay put? Find out in our free research report. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
Yahoo
24-04-2025
- Business
- Yahoo
Envista (NVST): Buy, Sell, or Hold Post Q4 Earnings?
Over the last six months, Envista shares have sunk to $15.51, producing a disappointing 18.5% loss - worse than the S&P 500's 8.1% drop. This was partly driven by its softer quarterly results and might have investors contemplating their next move. Is there a buying opportunity in Envista, or does it present a risk to your portfolio? See what our analysts have to say in our full research report, it's free. Despite the more favorable entry price, we're swiping left on Envista for now. Here are three reasons why NVST doesn't excite us and a stock we'd rather own. Uniting more than 30 trusted brands including Nobel Biocare, Ormco, and DEXIS under one corporate umbrella, Envista Holdings (NYSE:NVST) is a global dental products company that provides equipment, consumables, and specialized technologies for dental professionals. Investors interested in Dental Equipment & Technology companies should track constant currency revenue in addition to reported revenue. This metric excludes currency movements, which are outside of Envista's control and are not indicative of underlying demand. Over the last two years, Envista failed to grow its constant currency revenue. This performance was underwhelming and implies there may be increasing competition or market saturation. It also suggests Envista might have to lower prices or invest in product improvements to accelerate growth, factors that can hinder near-term profitability. Analyzing the long-term change in earnings per share (EPS) shows whether a company's incremental sales were profitable – for example, revenue could be inflated through excessive spending on advertising and promotions. Sadly for Envista, its EPS declined by 16.4% annually over the last five years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand. ROIC, or return on invested capital, is a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity). We like to invest in businesses with high returns, but the trend in a company's ROIC is what often surprises the market and moves the stock price. Over the last few years, Envista's ROIC has unfortunately decreased significantly. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between. We see the value of companies helping consumers, but in the case of Envista, we're out. Following the recent decline, the stock trades at 14.1× forward price-to-earnings (or $15.51 per share). This valuation tells us it's a bit of a market darling with a lot of good news priced in - we think there are better stocks to buy right now. We'd suggest looking at one of our top digital advertising picks. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Sterling Infrastructure (+1,096% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
